匹多莫德口服液治疗反复发作呼吸道感染患儿50例疗效观察  

PIDOTIMOD ORAL SOLUTION IN TREATMENT OF 50 CHILDREN WITH REITERATIVE RESPIRATORY TRACT INFECTIONS

作　　者：万丽英[1] 董传海[1] 邢军[1] 

机构地区：[1]山东省莱芜市人民医院,271100

出　　处：《中国煤炭工业医学杂志》2012年第2期205-207,共3页Chinese Journal of Coal Industry Medicine

摘　　要：目的观察匹多莫德口服液治疗反复呼吸道感染(RRSI)患儿的疗效。方法 89例RRSI患儿中反复上呼吸道感染48例,反复下呼吸道感染41例。89例(病例组)分为观察组和对照组,二组均给予青霉素及利巴韦林注射液常规治疗;观察组在上述常规治疗的基础上,同时给予匹多莫德口服液。观察二组临床疗效,并测定IgA,IgG,IgM,CD3+,CD4+,CD8+,CD4+/CD8+,IL-2,NK的水平。结果治疗后观察组总有效率90.0%(45/50),对照组总有效率33.3(13/39),二组比较差异有统计学意义(P<0.01)。观察组治疗后,IgA,IgG,IgM,CD3+,CD4+,CD8+,CD4+/CD8+,IL-2,NK值均明显增加(P<0.01)。结论匹多莫德口服液用于防治小儿RRSI有明显疗效,能有效地改善免疫学指标,无明显不良反应。Objective To observe the therapeutic effect of Pidotimod Oral Solution in treating children with reiterative respiratory tract infections. Methods 89 children with reiterative respiratory tract infections（RRSI） were separated into two groups,inchuding 48 children with upper RRSI and 41 children with inferior RRSI. 50 children in the treatment group received benzylpenicillin and ribavirin injection;and then, was furthermore treated with Pidotimod Oral Solution. The control group of 39 children received only the above conventional treatment without Pidotimod Oral Solution. The effect on two groups were observed and the IgA,IgG,IgM,CD3 ＋ ,CD4 ＋ ,CD8 ＋ , CD4 ＋/CD8 ＋ ,IL- 2,NK level in both groups were measured before and after the treatment. Results After treatment,The total effective rate of was 90.0% （45/50） in the treatment group,and 30.0 % （13/39） in the control group. There was a significant difference between the two groups（P〈0.01）. The an obviously increase in levels of IgA, IgG, IgM,CD3 ＋ , CD4 ＋ ,CD8 ＋ , CD4 ＋/CD8 ＋ , IL- 2, NK was found in treatment group before and after the treatment（P〈0.01）. Conclusion Pidotimod Oral Solution is an effective agent in the treatment ＇of RRSI without obvious adverse reaction.

关 键 词：呼吸道感染 药物疗法 维生素C 匹多莫德口服液 儿童 

分 类 号：R725.6[医药卫生—儿科]